SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue guidance, attributed to stronger demand for Amtagvi and Proleukin, is driving the discussion. Traders are largely upbeat about the commercial ramp and improving execution, while also watching for upcoming NSCLC data; short-squeeze and takeover talk remains speculative.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQures 48-month AMT-130 Huntingtons data is driving attention: the primary cUHDRS measure showed 44% slowing but did not reach statistical significance, while TFC showed 61% slowing. Traders are debating whether dropouts in the external control group explain the weaker result and whether the previously filed BLA can rely on 36-month data, versus concerns that the treatment effect is waning and approval prospects have weakened.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes allowing VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing are fueling concern that competition could weaken FICOs longstanding mortgage-scoring advantage and revenue. Traders are split between viewing the selloff as a lasting threat to the moat and calling it an overreaction, citing FICOs broader software business and continued growth.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and collaboration to test ivonescimab in combination cancer therapies are driving attention, with traders viewing the deal as financing support and a vote of confidence in the drug. Others caution that it is not an acquisition and does not determine the outcome of the pending FDA review, raising the possibility of a sell-the-news reaction.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas is drawing attention after the U.S. Army selected it for a program to develop next-generation, ultra-high-voltage silicon-carbide power semiconductors and validate a domestic manufacturing process. Many traders see the selection as important technology validation and are speculating about a short squeeze, while others caution that it is a prototype project with undisclosed financial termsnot a clear near-term revenue catalystand question whether the initial pop can hold.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp ZBCN move has sparked breakout and momentum chatter, with traders speculating that a possible Robinhood connection is behind it; that connection is not confirmed. Bulls also point to Zebecs payroll and payments integrations, while skeptics question whether partnerships are translating into enough real usage and token demand.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has fueled buyout speculation, though traders disagree on whether it signals a potential deal or is routine executive protection; the policy alone does not confirm an acquisition. The debate is compounded by frustration over limited updates and uncertainty around the next BlueBird shipment and launch schedule.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAX is drawing attention after a sharp rally and increased trading volume, with traders linking the move to altcoin momentum and Avalanches tokenization and institutional-adoption narrative. The community is split between expecting the breakout to continue and warning that the rise may be speculative and vulnerable to a pullback.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immixs interim NEXICART-2 update reporting an 89% complete-response rate across 45 patients, alongside strong results in the newly reported patients, is driving attention; traders largely view the data and reported safety profile favorably. The accompanying registered share offering has prompted some dilution concerns, tempering the bullish reaction.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK results for its experimental wet AMD treatments Zenkuda and KSI-501 are driving attention after both met primary endpoints, fueling a sharp rally and talk of a short squeeze. Traders are divided between optimism about the drugs potential and concerns about valuation, future financing and dilution, FDA approval, and competition from established treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy

(RTTNews) - Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for upto $47 million, helping advance the latter's pipeline, which includes AVC-201 for the treatment of relapsed/refr...

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare PartnersPR NewswireSAN DIEGO, Sept. 22, 2026 SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a...

Here's How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals has a marketread more...

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?

Equity

Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.

If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals has a marketread more...

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals has a marketread more...

Ligand Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $301.78, changing hands for $303.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $271.00, changing hands for $274.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

Ligand Pharmaceuticals Director Unloads 2,501 Shares  Should You Be Concerned?

Key PointsKozarich sold 2,501 common shares...

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

Key Points5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

LGND News